ae:I[454378,["$35","$36","$2a","$37","$38","$39","$3a","$3b","$3c","$3d","$3e","$2f","$2c","$3f","$30","$40","$2e","$41","$42","$43","$2d","$44","$45","$46","$47","$48","$49","$4a"],"default"] af:T461,According to the provided articles, the typical time it takes to heal gastroesophageal reflux disease (GERD) with treatment can vary: - Many surveys show up to 60% of the population suffers from GERD at some time [1]. - With proton pump inhibitor (PPI) treatment, 8 weeks is often required to heal most patients with erosive esophagitis [2, 3, 4]. - One study found 87.7% of erosive reflux disease patients had endoscopic healing after 4-8 weeks of PPI therapy, though healing was lower (72.4%) in those with Barrett's esophagus [5]. - Another study showed 80% healing of esophageal lesions after 4 weeks and 90% after 8 weeks with a PPI [6]. - H. pylori infection may increase healing rates - one study found 96.4% of H. pylori-positive patients healed after 8 weeks of PPI vs 91.8% of H. pylori-negative [7]. - For milder GERD, a PPI for 2-4 weeks can provide symptom resolution in many patients [8]. So in summary, while some patients may respond quicker, 4-8 weeks of PPI therapy is typically needed to achieve healing of erosive esophagitis from GERD, with potential for longer treatment required in certain cases.b0:T4d6,GERD is a common disease that has a significant impact on patients' quality of life. Many surveys have shown that up to 60% of the population suffers from GERD at some time. Heartburn and acid regurgitation are the classic symptoms, but manifestations are variable. Of the several extraesophageal manifestations of GERD, reflux-induced asthma may be the most important. Complications of GERD include peptic strictures of the esophagus and Barrett's metaplasia. Clinical diagnosis of GERD can be confirmed by response to antisecretory therapy. A high-dose trial of a PPI is becoming an accepted diagnostic technique for uncomplicated mild or moderate GERD. Endoscopic examination and ambulatory esophageal pH monitoring still have a role in the evaluation of severe GERD or when other diseases are suspected. Lifestyle changes rarely are beneficial, and antisecretory therapy remains the mainstay of GERD treatment. PPIs have been shown to be more effective than H2 blockers. Antireflux surgery is indicated in some patients. Healing of esophagitis can take up to 8 weeks; failure to control symptoms necessitates the use of higher drug doses. Failure to control symptoms with high-dose PPI treatment raises the likelihood of other causes.b1:T6d3,The aim of the study was to evaluate erosive esophagitis healing and symptom improvement with once-daily esomeprazole in children ages 12 to 36 months with endoscopically or histologically proven gastroesophageal reflux disease (GERD). Data from children ages 12 to 36 months were included in a post-hoc analysis of an 8-week, multicenter, randomized, and double-blind by dose strata study of patients ages 1 to 11 years with endoscopically or histologically confirmed GERD. Children were randomized to receive esomeprazole 5 or 10 mg once daily. Patients underwent endoscopy and, if required, mucosal biopsy at baseline. Patients who had erosive esophagitis (graded using the Los Angeles classification system) at baseline underwent a follow-up endoscopy at final study visit to assess healing of erosive esophagitis. Investigators scored severity of GERD symptoms at baseline and every 2 weeks using the Physician Global Assessment. Thirty-one of 109 primary study patients ages 12 to 36 months were included in the post hoc analysis. At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment. Of the 19 patients with moderate-to-severe baseline Physician Global Assessment symptom scores, 84.2% had lower scores by the final visit. Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit (P ≤ 0.0018). Esomeprazole 5 or 10 mg may be used to successfully treat erosive esophagitis and symptoms of GERD in children as young as 1 year. Moreover, although not yet validated in pediatric patients, the Los Angeles classification system was useful in grading erosive esophagitis in children ages 12 to 36 months.b2:T6d3,The aim of the study was to evaluate erosive esophagitis healing and symptom improvement with once-daily esomeprazole in children ages 12 to 36 months with endoscopically or histologically proven gastroesophageal reflux disease (GERD). Data from children ages 12 to 36 months were included in a post-hoc analysis of an 8-week, multicenter, randomized, and double-blind by dose strata study of patients ages 1 to 11 years with endoscopically or histologically confirmed GERD. Children were randomized to receive esomeprazole 5 or 10 mg once daily. Patients underwent endoscopy and, if required, mucosal biopsy at baseline. Patients who had erosive esophagitis (graded using the Los Angeles classification system) at baseline underwent a follow-up endoscopy at final study visit to assess healing of erosive esophagitis. Investigators scored severity of GERD symptoms at baseline and every 2 weeks using the Physician Global Assessment. Thirty-one of 109 primary study patients ages 12 to 36 months were included in the post hoc analysis. At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment. Of the 19 patients with moderate-to-severe baseline Physician Global Assessment symptom scores, 84.2% had lower scores by the final visit. Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit (P ≤ 0.0018). Esomeprazole 5 or 10 mg may be used to successfully treat erosive esophagitis and symptoms of GERD in children as young as 1 year. Moreover, although not yet validated in pediatric patients, the Los Angeles classification system was useful in grading erosive esophagitis in children ages 12 to 36 months.b3:T717,Adequacy of acid suppression is a critical factor influencing healing in gastro-oesophageal reflux disease (GORD). The European prospective study ProGORD was set up to determine the endoscopic and symptomatic progression of GORD over five years under routine care, after initial acid suppression with esomeprazole. We report on factors influencing endoscopic healing and symptom resolution during the acute treatment phase. Patients with symptoms suggestive of GORD underwent endoscopy and biopsies were obtained from the oesophagus for diagnosis of abnormalities, including Barrett's oesophagus (BO). Data from 6215 patients were included in the "intention to treat" analysis, 3245 diagnosed as having erosive reflux disease (ERD) and 2970 non-erosive reflux disease (NERD). ERD patients were treated with esomeprazole 40 mg for 4-8 weeks for endoscopic healing while NERD patients received 20 mg for 2-4 weeks for resolution of heartburn symptoms. Endoscopic healing occurred overall in 87.7% of ERD patients although healing was significantly lower in those with more severe oesophagitis (76.9%) and in those with BO (72.4%), particularly in Helicobacter pylori negative BO patients (70.1%). Age, sex, and body mass index appeared to have no significant impact on healing. Complete heartburn resolution was reported by 70.4% of ERD patients and by 64.8% of NERD patients at the last visit. Only H pylori infection had a significant influence on complete heartburn resolution in the NERD group (68.1% and 63.7% for H pylori positive and H pylori negative, respectively; p = 0.03). The presence of Barrett's mucosa, as well as severe mucosal damage, exerts a negative impact on healing. H pylori infection had a positive influence on healing in ERD patients with coexistent BO but no influence on those without BO.b4:T641,To investigate the efficacy of a low dose of pantoprazole, a gastric proton pump inhibitor, for the relief of symptoms and healing of lesions in mild gastro-oesophageal reflux disease (GERD), and to compare it with the efficacy of ranitidine. Patients with endoscopically established GERD (Stage I, Savary-Miller classification) were enrolled into a randomized, double-blind, parallel-group and multicentre study (intention-to-treat n = 209, age range 19-82 years). They were treated once daily with oral pantoprazole 20 mg or ranitidine 300 mg, for up to 8 weeks. End-point parameters included relief of symptoms (heartburn, acid regurgitation, pain on swallowing) and the healing of GERD lesions. Relief from symptoms was assessed after 2 and 4 weeks, and endoscopically confirmed healing of lesions after 4 and 8 weeks. The proportion of patients reporting complete relief from symptoms after 2 weeks was greater in the pantoprazole than in the ranitidine group (69 vs. 48%, P < 0.01), with further improvements seen in the pantoprazole group after 4 weeks (80 vs. 65%, P < 0.05, Cochran-Mantel/Haenszel test). Healing of lesions was confirmed in 70/87 (80%) patients after 4 weeks (pantoprazole group), as compared with 55/86 (64%) patients (ranitidine group) (P < 0.05, per protocol population); after 8 weeks the respective results were 78/87 (90%) and 63/86 (73%) patients (P < 0.01). Both study medications were well tolerated. Low-dose pantoprazole (20 mg) is clinically superior to ranitidine (300 mg) in providing fast relief from symptoms and healing of lesions in patients with mild GERD.b5:T7f9,In previous studies an exaggerated effect of proton pump inhibitors (PPIs) on intragastric pH in Helicobacter pylori-infected patients was observed. Because healing and improvement of symptoms in patients with gastroesophageal reflux disease (GERD) is directly associated with an increase of intragastric pH during treatment, we hypothesized that the response to treatment with a PPI in patients with reflux esophagitis would be better in H. pylori-infected patients than in patients without H. pylori infection. We recruited 971 patients with endoscopically verified reflux esophagitis grades II and III (Savary/Miller). At study entry, H. pylori status was assessed by a 13C-urea breath test and baseline characteristics were recorded. Physicians and patients were not notified about the results of the breath test until completion of the study. All patients underwent treatment with pantoprazole, 40 mg orally once daily for 4 weeks. Healing was verified by endoscopy after 4 or 8 weeks of treatment. If the esophagitis had not completely healed at this time, treatment was continued for a further 4-week period. Healing rates and symptom relief were compared for patients with and without H. pylori infection. The prevalence of H. pylori was 39.9% (95% confidence interval [CI], 36.9-42.9), and neither gender, smoking, nor alcohol consumption were associated with the H. pylori infection (P > 0.4). The trial was completed by 846 patients without protocol violation. Overall healing rates of reflux esophagitis were 80.4% (95% CI, 77.7-83.1) and 93.6% (95% CI, 91.8-95.2) after 4 and 8 weeks, respectively. In H. pylori-positive patients, healing rates were significantly higher after 4 (86.6% vs. 76.3%; P = 0.0005) and 8 weeks (96.4% vs. 91.8%; P < 0.004). Relief of symptoms after 4 weeks was also significantly (P < 0.05) better in H. pylori-infected patients than in uninfected patients. Patients with reflux esophagitis and H. pylori infection respond significantly better than H. pylori-negative patients to the PPI pantoprazole.b6:T90b,Gastroesophageal reflux disease (GERD) in primary care practice presents symptomatically, and resources to distinguish promptly between erosive esophagitis and endoscopy-negative reflux disease (ENRD) are limited. It is therefore important to determine the roles of proton pump inhibitors and histamine-2-receptor antagonists for first-line symptom-based therapy in patients with erosive esophagitis and ENRD. The aim of this study was to compare pantoprazole 40 mg once daily versus nizatidine 150 mg b.i.d. in a mixed GERD patient population with ENRD or erosive esophagitis (Savary-Miller grades 1-3). A 4-wk randomized, double-blind, parallel-group, multicenter study conducted in Canada. Eligible patients had experienced GERD symptoms > or = 4 times weekly for > 6 months. Patients were randomized to pantoprazole 40 mg once daily or nizatidine 150 mg b.i.d.. Endoscopy was performed before randomization and after 4 wk of therapy. Of 220 patients randomized to therapy, 208 were available for a modified intent-to-treat analysis. Erosive esophagitis was present in 125 patients; 35 patients were Helicobacter pylori positive. There was complete symptom relief after 7 days of therapy in 14% of patients on nizatidine and in 40% of those on pantoprazole (p < 0.0001), and after 28 days of treatment in 36% and 63% of patients, respectively (p < 0.0001). After 28 days of treatment, adequate heartburn control was reported by 58% of the nizatidine group and in 88% of the pantoprazole (p < 0.0001); erosive esophagitis healing rates were 44% for nizatidine and 79% for pantoprazole (p < 0.001). Rescue antacid was needed by a greater number of patients using nizatidine than of those using pantoprazole (p < 0.001). H. pylori infection was associated with an increased probability of erosive esophagitis healing. Pantoprazole once daily was superior to nizatidine b.i.d. in producing complete heartburn relief in a mixed population of GERD patients and in achieving erosion healing. The proportions of patients with complete symptom relief were greater with pantoprazole after 7 days of therapy than with nizatidine after 28 days. The present study data suggest that pantoprazole is a highly effective first-line therapy for the management of gastroesophageal reflux disease in a primary care practice setting.50:[["$","$Lae",null,{"initialQaList":[{"id":"","streamId":"","question":"How long does it take to heal GERD?","answer":"$af","articles":[{"title":"Gastroesophageal reflux disease. Control of symptoms, prevention of complications.","url":"https://pubmed.ncbi.nlm.nih.gov/11570205/","authors":["A Kaynard","K Flora"],"year":2001,"type":"SCIENTIFIC","snippet":"$b0","score":0.9965306397577314,"journal":"Postgraduate medicine","n_citations":2,"tldr":"The variable presentations, identification, and treatment of Gastroesophageal reflux disease are discussed.","highlighted_text":"","quantitative_data":"Many surveys have shown that up to 60% of the population suffers from GERD at some time.","is_high_quality_source":"False","images":[],"nCitations":2,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"Many surveys have shown that up to 60% of the population suffers from GERD at some time.","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":false,"id":"c648d69c-0173-47e1-b94e-6cf678c63339"},{"title":"Management of gastroesophageal reflux disease.","url":"https://pubmed.ncbi.nlm.nih.gov/12712217/","authors":["V Stanghellini"],"year":2003,"type":"SCIENTIFIC","snippet":"Gastroesophageal reflux disease (GERD) is a frequent clinical condition which leads to reduced quality of life. Atypical manifestations of the disease can confound diagnosis, and even the typical symptoms of heartburn and regurgitation can lead to misinterpretation. Proton pump inhibitors (PPIs) are the standard treatment for GERD and the different formulations show equivalence on a milligram to milligram basis in terms of efficacy and tolerability. With standard dosing, 8 weeks of treatment has been shown to heal most patients. However, as GERD is a chronically relapsing disease, maintenance treatment with lower dose PPIs is frequently required. Pantoprazole is the only PPI found not to interact with the metabolism of other drugs and is therefore the treatment of choice especially for patients with co-morbidities and co-medication.","score":0.9908702543025921,"journal":"Drugs of today (Barcelona, Spain : 1998)","n_citations":0,"tldr":"Pantoprazole is the only PPI found not to interact with the metabolism of other drugs and is therefore the treatment of choice especially for patients with co-morbidities and co-medication.","highlighted_text":"","quantitative_data":"With standard dosing, 8 weeks of treatment has been shown to heal most patients.","is_high_quality_source":"False","images":[],"nCitations":0,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"With standard dosing, 8 weeks of treatment has been shown to heal most patients.","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":false,"id":"bbeb9cce-9c93-4bf1-b898-490b60ca0f7a"},{"title":"Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.","url":"https://pubmed.ncbi.nlm.nih.gov/20706150/","authors":["Vasundhara Tolia","Mark A Gilger","Peter N Barker","Marta Illueca"],"year":2010,"type":"SCIENTIFIC","snippet":"$b1","score":0.9407338444443517,"journal":"Journal of pediatric gastroenterology and nutrition","n_citations":4,"tldr":"Once-daily esomeprazole was found to successfully treat erosive esophagitis and symptoms of GERD in children ages 12 to 36 months, with 48.4% of patients with erosive esophagitis being healed after 8 weeks of treatment.","highlighted_text":"","quantitative_data":"At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment.","is_high_quality_source":"False","images":[],"nCitations":4,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment.","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":false,"id":"a2362044-1958-4537-a7a3-e5c92ec65334"},{"title":"Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.","url":"https://pubmed.ncbi.nlm.nih.gov/26121348/","authors":["Vasundkara Tolia","Mark A Gilger","Peter N Barker","Marta Illueca"],"year":2015,"type":"SCIENTIFIC","snippet":"$b2","score":0.9406243107887893,"journal":"Journal of pediatric gastroenterology and nutrition","n_citations":0,"tldr":"Following esomeprazole treatment, GERD symptoms were significantly improved from baseline to final visit and the Los Angeles classification system was useful in grading erosive esophagitis in children ages 12 to 36 months.","highlighted_text":"","quantitative_data":"At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment.","is_high_quality_source":"False","images":[],"nCitations":0,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"At baseline, 15 patients (48.4%) had erosive esophagitis, underwent follow-up endoscopy, and were healed after 8 weeks of esomeprazole treatment.","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":false,"id":"c4d2387e-9440-435f-a8a1-0db4a625fc54"},{"title":"Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.","url":"https://pubmed.ncbi.nlm.nih.gov/15888776/","authors":["P Malfertheiner","T Lind","S Willich","M Vieth","D Jaspersen","J Labenz","W Meyer-Sabellek","O Junghard","M Stolte"],"year":2005,"type":"SCIENTIFIC","snippet":"$b3","score":0.9884962398401953,"journal":"Gut","n_citations":15,"tldr":"H pylori infection had a positive influence on healing in ERD patients with coexistent BO but no influence on those without BO, and the presence of Barrett’s mucosa exerts a negative impact on healing.","highlighted_text":"","quantitative_data":"Endoscopic healing occurred overall in 87.7% of ERD patients although healing was significantly lower in those with more severe oesophagitis (76.9%) and in those with BO (72.4%), particularly in Helicobacter pylori negative BO patients (70.1%).","is_high_quality_source":"True","images":[],"nCitations":15,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"Endoscopic healing occurred overall in 87.7% of ERD patients although healing was significantly lower in those with more severe oesophagitis (76.9%) and in those with BO (72.4%), particularly in Helicobacter pylori negative BO patients (70.1%).","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":true,"id":"1749b1bf-047c-4c2f-9bb7-db855d21d183"},{"title":"Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis.","url":"https://pubmed.ncbi.nlm.nih.gov/9768529/","authors":["A Dettmer","R Vogt","F Sielaff","R Lühmann","A Schneider","R Fischer"],"year":1998,"type":"SCIENTIFIC","snippet":"$b4","score":0.9596206104368582,"journal":"Alimentary pharmacology & therapeutics","n_citations":8,"tldr":"To investigate the efficacy of a low dose of pantoprazole, a gastric proton pump inhibitor, for the relief of symptoms and healing of lesions in mild gastro‐oesophageal reflux disease (GERD), and to compare it with the effectiveness of ranitidine.","highlighted_text":"","quantitative_data":"Healing of lesions was confirmed in 70/87 (80%) patients after 4 weeks (pantoprazole group), as compared with 55/86 (64%) patients (ranitidine group) (P < 0.05, per protocol population); after 8 weeks the respective results were 78/87 (90%) and 63/86 (73%) patients (P < 0.01).","is_high_quality_source":"True","images":[],"nCitations":8,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"Healing of lesions was confirmed in 70/87 (80%) patients after 4 weeks (pantoprazole group), as compared with 55/86 (64%) patients (ranitidine group) (P < 0.05, per protocol population); after 8 weeks the respective results were 78/87 (90%) and 63/86 (73%) patients (P < 0.01).","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":true,"id":"f5971718-d6b7-40e8-a4ca-bf98a6316392"},{"title":"Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.","url":"https://pubmed.ncbi.nlm.nih.gov/10381904/","authors":["G Holtmann","C Cain","P Malfertheiner"],"year":1999,"type":"SCIENTIFIC","snippet":"$b5","score":0.9828230164829457,"journal":"Gastroenterology","n_citations":4,"tldr":"Patients with reflux esophagitis and H. pylori infection respond significantly better than H.pylori-negative patients to the PPI pantoprazole, and Relief of symptoms after 4 weeks was also significantly (P < 0.05) better in H. mlyori- infected patients than in uninfected patients.","highlighted_text":"","quantitative_data":"In H. pylori-positive patients, healing rates were significantly higher after 4 (86.6% vs. 76.3%; P = 0.0005) and 8 weeks (96.4% vs. 91.8%; P < 0.004).","is_high_quality_source":"False","images":[],"nCitations":4,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"In H. pylori-positive patients, healing rates were significantly higher after 4 (86.6% vs. 76.3%; P = 0.0005) and 8 weeks (96.4% vs. 91.8%; P < 0.004).","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":false,"id":"b0e9d9eb-3c10-4e89-839a-0ed0f3373066"},{"title":"Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.","url":"https://pubmed.ncbi.nlm.nih.gov/11695354/","authors":["D Armstrong","P Paré","D Pericak","M Pyzyk"],"year":2001,"type":"SCIENTIFIC","snippet":"$b6","score":0.9335999451071854,"journal":"The American journal of gastroenterology","n_citations":20,"tldr":"The present study data suggest that pantoprazole is a highly effective first-line therapy for the management of gastroesophageal reflux disease in a primary care practice setting and in achieving erosion healing.","highlighted_text":"","quantitative_data":"There was complete symptom relief after 7 days of therapy in 14% of patients on nizatidine and in 40% of those on pantoprazole (p < 0.0001), and after 28 days of treatment in 36% and 63% of patients, respectively (p < 0.0001).","is_high_quality_source":"True","images":[],"nCitations":20,"pmcUrl":"$undefined","documentId":"$undefined","chunkId":"$undefined","sentStart":"$undefined","sentEnd":"$undefined","citedText":"$undefined","citationLabel":"$undefined","org":"$undefined","orgFullName":"$undefined","documentTypes":"$undefined","highlightedText":"","quantitativeData":"There was complete symptom relief after 7 days of therapy in 14% of patients on nizatidine and in 40% of those on pantoprazole (p < 0.0001), and after 28 days of treatment in 36% and 63% of patients, respectively (p < 0.0001).","recommendationSummaries":"$undefined","sourceContext":"$undefined","citedPassage":"$undefined","isHighQualitySource":true,"id":"3b900d5d-36a2-45f2-9999-a6dcd831b7fa"}],"images":"$undefined","uploadedFiles":"$undefined","expandedImages":false,"followUps":[],"showAllSources":false,"modelName":"standard","filters":"$undefined","searchStrings":[],"analyzedReferences":[],"articlesReceived":true}],"pageShareId":"mUzMvkadev9Eq589Fz88eg"}],"$Lb7"]